Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 8Breast Neoplasms 5Stomach Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Rectal Neoplasms 2Colonic Neoplasms 2Adenocarcinoma Of Esophagus 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Triple Negative Breast Neoplasms 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Biliary Tract Neoplasms 1Adenocarcinoma 1

Interventions

zidovudine 5'-monophosphate-mannose-albumin conjugate 1tucatinib 1niraparib 1galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20 1abemaciclib 1Trastuzumab 1Tissue Banks 1Ringer's acetate 1Immunoglobulins, Intravenous 1Fulvestrant 1Diet 1Blood Specimen Collection 1Biological Therapy 1Albumins 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × tucatinib × Gastrointestinal × Clear all
NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡